| MeSH term | MeSH ID | Detail |
|---|---|---|
| Amenorrhea | D000568 | 4 associated lipids |
| Amputation, Traumatic | D000673 | 2 associated lipids |
| Anemia | D000740 | 21 associated lipids |
| Anemia, Aplastic | D000741 | 6 associated lipids |
| Anemia, Hemolytic | D000743 | 4 associated lipids |
| Anemia, Hemolytic, Autoimmune | D000744 | 5 associated lipids |
| Anemia, Refractory | D000753 | 3 associated lipids |
| Anemia, Refractory, with Excess of Blasts | D000754 | 2 associated lipids |
| Aneurysm, Dissecting | D000784 | 2 associated lipids |
| Angiolymphoid Hyperplasia with Eosinophilia | D000796 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Morris RE et al. | Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. | 1990 | Transplant. Proc. | pmid:1689885 |
| Li PK et al. | The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. | 1990 | Adverse Drug React Acute Poisoning Rev | pmid:1703724 |
| Todo S et al. | Early trials with FK 506 as primary treatment in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689886 |
| McCauley J et al. | The effects of FK 506 on renal function after liver transplantation. | 1990 | Transplant. Proc. | pmid:1689887 |
| Kang Y et al. | Acute hemodynamic effects of FK 506 during and after orthotopic liver transplantation. | 1990 | Transplant. Proc. | pmid:1689889 |
| Jain AB et al. | FK 506 dosage in human organ transplantation. | 1990 | Transplant. Proc. | pmid:1689890 |
| Demetris AJ et al. | Pathologic observations in human allograft recipients treated with FK 506. | 1990 | Transplant. Proc. | pmid:1689891 |
| Shapiro R et al. | The side effects of FK 506 in humans. | 1990 | Transplant. Proc. | pmid:1689892 |
| Van Thiel DH et al. | Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. | 1990 | Transplant. Proc. | pmid:1689893 |
| Hoffman AL et al. | The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. | 1990 | Transplantation | pmid:1690469 |
| Woo J et al. | The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. | 1990 | Scand. J. Immunol. | pmid:1690915 |
| Yasunami Y et al. | FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. | 1990 | Transplantation | pmid:1691535 |
| Metcalfe SM and Richards FM | Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. | 1990 | Transplantation | pmid:1691537 |
| Morimoto T et al. | Pancreaticoduodenal allotransplantation with FK 506 in the dog. | 1990 | Transplant. Proc. | pmid:1691550 |
| Yasunami Y et al. | Characterization of the immunosuppressive activity of FK 506 in rat islet allografts. | 1990 | Transplant. Proc. | pmid:1691557 |
| Thomson AW | FK-506 enters the clinic. | 1990 | Immunol. Today | pmid:1692221 |
| Saitoh Y et al. | Morphological rejection phases and cytotoxic activity in peripheral blood lymphocytes in canine lung allo-transplantation. | 1990 | Jpn J Surg | pmid:1692892 |
| Rosen MK et al. | Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate. | 1990 | Science | pmid:1693013 |
| Murase N et al. | Prevention of spontaneous diabetes in BB rats with FK 506. | 1990 | Lancet | pmid:1697397 |
| Justice RM et al. | The detection of proline isomerase activity in FK506-binding protein by two-dimensional 1H NMR exchange spectroscopy. | 1990 | Biochem. Biophys. Res. Commun. | pmid:1697463 |
| Todo S et al. | Liver, kidney, and thoracic organ transplantation under FK 506. | 1990 | Ann. Surg. | pmid:1697743 |
| Sakr MF et al. | FK 506 ameliorates the hepatic injury associated with ischemia. | 1990 | Life Sci. | pmid:1698241 |
| Kurasawa K et al. | The immunosuppressant FK-506 prevents progression of diabetes in nonobese diabetic mice. | 1990 | Clin. Immunol. Immunopathol. | pmid:1698584 |
| Miyagawa J et al. | Preventive effect of a new immunosuppressant FK-506 on insulitis and diabetes in non-obese diabetic mice. | 1990 | Diabetologia | pmid:1698679 |
| Lagodzinski Z et al. | Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice. | 1990 | Immunology | pmid:1698713 |
| Kawashima H et al. | Antigen-specific suppressor cells induced by FK506 in experimental autoimmune uveoretinitis in the rat. | 1990 | Invest. Ophthalmol. Vis. Sci. | pmid:1702408 |
| Wilkinson PC and Watson EA | FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes. | 1990 | Immunology | pmid:1702750 |
| Metcalfe S and Milner J | Phosphatases PP1 and PP2A act after the G0/G1 interface in lymphocyte activation. | 1990 | Immunol. Lett. | pmid:1702753 |
| Takada K et al. | Determination of a novel potent immunosuppressant (FK-506) in rat serum and lymph by high-performance liquid chromatography with chemiluminescence detection. | 1990 | J. Chromatogr. | pmid:1703552 |
| Woo J et al. | Antigen presentation and HLA-DR expression by FK-506-treated human monocytes. | 1990 | Immunology | pmid:1703987 |
| Wasik M et al. | Effect of FK-506 and cyclosporine on human T and B lymphoproliferative responses. | 1990 Jul-Aug | Immunopharmacology | pmid:1699911 |
| MacLeod AM and Thomson AW | [FK-506. A new immunosuppressive drug]. | 1990 Jul-Sep | Medicina (Firenze) | pmid:1706817 |
| Naouri A and Tissot E | [Indications for liver transplantation in adults]. | 1990 Jun-Jul | J Chir (Paris) | pmid:1698800 |
| Gailliot FP et al. | Fluidized bed adsorption for whole broth extraction. | 1990 Sep-Oct | Biotechnol. Prog. | pmid:1366874 |
| Goto T et al. | FK 506: historical perspectives. | 1991 | Transplant. Proc. | pmid:1721254 |
| Ochiai T et al. | Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. | 1991 | Transplant. Proc. | pmid:1721255 |
| Siekierka JJ et al. | Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. | 1991 | Transplant. Proc. | pmid:1721256 |
| Morris RE | In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. | 1991 | Transplant. Proc. | pmid:1721257 |
| Kobayashi M et al. | FK 506 assay past and present--characteristics of FK 506 ELISA. | 1991 | Transplant. Proc. | pmid:1721258 |
| Warty VS et al. | Practical aspects of FK 506 analysis (Pittsburgh experience). | 1991 | Transplant. Proc. | pmid:1721259 |
| Müller MK et al. | Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. | 1991 | Transplant. Proc. | pmid:1721286 |
| Francavilla A et al. | The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. | 1991 | Transplant. Proc. | pmid:1721287 |
| Blanc P et al. | Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. | 1991 | Transplant. Proc. | pmid:1721288 |
| Loréal O et al. | FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. | 1991 | Transplant. Proc. | pmid:1721289 |
| McCauley J et al. | Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. | 1991 | Transplant. Proc. | pmid:1721290 |
| McLachlan G et al. | Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721291 |
| Yagihashi A et al. | The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721318 |
| Woo J et al. | Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. | 1991 | Transplant. Proc. | pmid:1721319 |
| Chen-Woan M et al. | Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721320 |
| Fukuzawa M et al. | Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. | 1991 | Transplant. Proc. | pmid:1721321 |
| Takaori K et al. | Effects of FK 506 on in vivo immunity in comparison to cyclosporine. | 1991 | Transplant. Proc. | pmid:1721322 |
| Felser I et al. | Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721350 |
| Alessiani M et al. | CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721351 |
| Green M et al. | Infectious complications of pediatric liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721352 |
| Torre-Cisneros J et al. | The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. | 1991 | Transplant. Proc. | pmid:1721353 |
| Paul AA et al. | CMV retinitis and the use of FK 506. | 1991 | Transplant. Proc. | pmid:1721354 |
| Reyes J et al. | Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721355 |
| Frayha HH et al. | Lymphoproliferative disorder in a liver transplant patient on FK 506. | 1991 | Lancet | pmid:1703258 |
| Burman K and Crawford DH | Effect of FK 506 on Epstein-Barr virus specific cytotoxic T cells. | 1991 | Lancet | pmid:1703259 |
| Nalesnik MA et al. | Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. | 1991 | Transplant. Proc. | pmid:1703335 |
| Armitage JM et al. | A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1703336 |
| Gordon RD et al. | Liver transplantation under cyclosporine: a decade of experience. | 1991 | Transplant. Proc. | pmid:1703339 |
| Moutabarrik A et al. | FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. | 1991 | Transplant. Proc. | pmid:1721382 |
| Moutabarrik A et al. | In vitro FK 506 kidney tubular cell toxicity. | 1991 | Transplant. Proc. | pmid:1721383 |
| McCauley J et al. | Changes in renal function after liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721385 |
| Tauxe WN et al. | A comparison of the renal effects (ERPF, GFR, and FF) of FK 506 and cyclosporine in patients with liver transplantation. | 1991 | Transplant. Proc. | pmid:1721386 |
| McCauley J et al. | Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721387 |
| Ohtsuka S et al. | The effect of short-term FK 506 therapy on pancreas transplantation in rats. | 1991 | Transplant. Proc. | pmid:1721413 |
| Yamashita T et al. | Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. | 1991 | Transplant. Proc. | pmid:1721414 |
| Fukuzaki T et al. | Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. | 1991 | Transplant. Proc. | pmid:1721415 |
| Tzakis AG et al. | FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721416 |
| Masaoka T et al. | Phase II study of FK 506 for allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721417 |
| Markus PM et al. | The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721418 |
| Ziccardi VB et al. | Maxillofacial considerations in orthotopic liver transplantation. | 1991 | Oral Surg. Oral Med. Oral Pathol. | pmid:1704494 |
| Bierer BE et al. | The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. | 1991 | Eur. J. Immunol. | pmid:1705513 |
| Heitman J et al. | FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1705713 |
| Goebl MG | The peptidyl-prolyl isomerase, FK506-binding protein, is most likely the 12 kd endogenous inhibitor 2 of protein kinase C. | 1991 | Cell | pmid:1706222 |
| de Paulis A et al. | FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. | 1991 | J. Immunol. | pmid:1706398 |
| Lin CY et al. | Effects of FK 506 on the biochemical markers in canine lung allograft rejection. | 1991 | Transplant. Proc. | pmid:1721445 |
| Propper DJ et al. | Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. | 1991 | Transplant. Proc. | pmid:1721446 |
| Fabrega AJ et al. | FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. | 1991 | Transplant. Proc. | pmid:1721447 |
| Davies CB et al. | Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. | 1991 | Transplant. Proc. | pmid:1721448 |
| Abu-Elmagd K et al. | FK 506: a new therapeutic agent for severe recalcitrant psoriasis. | 1991 | Transplant. Proc. | pmid:1721449 |
| Nikolaidis NL et al. | Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. | 1991 | Transplant. Proc. | pmid:1721450 |
| Sigal NH et al. | Inhibition of human T-cell activation by FK 506, rapamycin, and cyclosporine A. | 1991 | Transplant. Proc. | pmid:1712132 |
| Fung JJ et al. | Current status of FK 506 in liver transplantation. | 1991 | Transplant. Proc. | pmid:1712133 |
| Francavilla A et al. | Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. | 1991 | Hepatology | pmid:1712337 |
| Aoki H | [FK 506, a new immunosuppressant produced by a Streptomyces]. | 1991 | Nippon Rinsho | pmid:1712403 |
| Hultsch T et al. | Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. | 1991 | Proc. Natl. Acad. Sci. U.S.A. | pmid:1712484 |
| Nielsen JB et al. | Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. | 1991 | Biochemistry | pmid:2043618 |
| Ochiai T et al. | [Immunosuppressive agents--advances of the developmental studies and the mode of action]. | 1991 | Nippon Rinsho | pmid:1715926 |
| Jiang H et al. | Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. | 1991 | Eur Surg Res | pmid:1723683 |
| Liu J et al. | Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. | 1991 | Cell | pmid:1715244 |
| Sakai K et al. | [The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents--comparison with cyclosporin A]. | 1991 | No To Shinkei | pmid:1716937 |
| Henderson DJ et al. | Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. | 1991 | Immunology | pmid:1715317 |
| DeFranco AL | Signal transduction. Immunosuppressants at work. | 1991 | Nature | pmid:1715515 |
| Flanagan WM et al. | Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. | 1991 | Nature | pmid:1715516 |
| Fujino Y et al. | FK506 treatment of S-antigen induced uveitis in primates. | 1991 | Curr. Eye Res. | pmid:1717199 |
| McWhinnie DL and Morris PJ | Combination drug therapies for immunosuppression in transplantation. | 1991 | Ann. Acad. Med. Singap. | pmid:1724724 |
| Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |